The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...
MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7 billion bid to acquire Terns Pharma. The Financial Times first reported that talks between the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results